Research Analysts Offer Predictions for SLDB FY2026 Earnings

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Solid Biosciences in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings of ($2.13) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $16.00 target price on the stock. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.06).

Other equities analysts have also issued reports about the company. HC Wainwright boosted their price target on Solid Biosciences from $16.00 to $20.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. JPMorgan Chase & Co. cut their target price on Solid Biosciences from $12.00 to $11.00 and set an "overweight" rating on the stock in a research report on Thursday, March 13th. Piper Sandler cut their target price on Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating on the stock in a research report on Friday, May 16th. Wedbush cut their target price on Solid Biosciences from $18.00 to $17.00 and set an "outperform" rating on the stock in a research report on Friday, May 16th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $15.00 target price on shares of Solid Biosciences in a research report on Friday, June 6th. Ten analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $14.90.

Solid Biosciences Price Performance

Solid Biosciences stock traded down $0.22 during midday trading on Tuesday, hitting $4.61. 1,610,771 shares of the company were exchanged, compared to its average volume of 1,138,301. The company's fifty day moving average price is $3.19 and its 200-day moving average price is $3.97. The company has a market cap of $357.34 million, a PE ratio of -1.52 and a beta of 2.22. Solid Biosciences has a fifty-two week low of $2.41 and a fifty-two week high of $10.37.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in SLDB. Rhumbline Advisers grew its stake in Solid Biosciences by 10.5% during the 4th quarter. Rhumbline Advisers now owns 43,677 shares of the company's stock worth $175,000 after buying an additional 4,161 shares during the last quarter. Quantum Private Wealth LLC boosted its position in Solid Biosciences by 81.8% during the 4th quarter. Quantum Private Wealth LLC now owns 57,333 shares of the company's stock worth $229,000 after acquiring an additional 25,800 shares during the period. American Century Companies Inc. boosted its position in Solid Biosciences by 12.3% during the 4th quarter. American Century Companies Inc. now owns 46,857 shares of the company's stock worth $187,000 after acquiring an additional 5,126 shares during the period. Sei Investments Co. acquired a new position in Solid Biosciences during the 4th quarter worth $52,000. Finally, Prudential Financial Inc. boosted its position in Solid Biosciences by 71.3% during the 4th quarter. Prudential Financial Inc. now owns 109,105 shares of the company's stock worth $436,000 after acquiring an additional 45,400 shares during the period. 81.46% of the stock is currently owned by institutional investors.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.